Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma

by | Nov 29, 2023 | Myeloma News | 0 comments

Source: Pharmacy Times articles

Belantamab mafodotin (Blenrep; GlaxoSmithKline) demonstrated that, when combined with bortezomib and dexamethasone (BorDex), the time to disease progression or death was extended.
Read More

Submit a Comment